Xbrane Biopharma AB (publ)
SSE:XBRANE.ST
2.08 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Xbrane Biopharma AB (publ) |
Symbool | XBRANE.ST |
Munteenheid | SEK |
Prijs | 2.085 |
Beurswaarde | 61,989,344 |
Dividendpercentage | 0% |
52-weken bereik | 1.19 - 104.2 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Siavash Bashiri |
Website | https://www.xbrane.com |
An error occurred while fetching data.
Over Xbrane Biopharma AB (publ)
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)